Neuralstem, Inc. (CUR) Sees Significant Increase in Short Interest
Neuralstem, Inc. (NASDAQ:CUR) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,413,759 shares, an increase of 136.4% from the November 30th total of 598,032 shares. Based on an average daily volume of 6,510,771 shares, the days-to-cover ratio is presently 0.2 days. Currently, 11.3% of the shares of the company are short sold.
A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Neuralstem by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock valued at $2,000,000 after purchasing an additional 3,853 shares during the last quarter. Blair William & Co. IL lifted its position in Neuralstem by 171.0% in the 2nd quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock valued at $506,000 after purchasing an additional 55,115 shares during the last quarter. Finally, National Asset Management Inc. lifted its position in Neuralstem by 9.2% in the 2nd quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock valued at $134,000 after purchasing an additional 1,937 shares during the last quarter. Hedge funds and other institutional investors own 7.05% of the company’s stock.
Shares of Neuralstem (NASDAQ CUR) opened at $1.72 on Friday. The firm has a market cap of $26.05, a PE ratio of -1.04 and a beta of 1.63. Neuralstem has a 52-week low of $0.88 and a 52-week high of $6.60.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with Analyst Ratings Network's FREE daily email newsletter.